Table 1. Clinical and cellular characteristics of polymyositis patients.
| Patient | Sex | Age (years) | Disease duration (months) | Treatment | CK [U/L] | Frequency of CD8+NKG2Dhigh (%) |
|---|---|---|---|---|---|---|
| PM1 | M | 55 | 15 | IVIG | 2493 | 12,3 |
| PM2 | M | 43 | 11 | Pred | 112 | 4,97 |
| PM3 | M | 64 | 144 | MTX + IVIG | 560 | 10,3 |
| PM4 | F | 57 | 5 | IVIG | 69 | 8,82 |
| PM5 | M | 30 | 3 | CP | 356 | 9,85 |
| PM6 | M | 44 | 6 | Pred | 183 | 8,62 |
| PM7 | M | 56 | 19 | Aza | 53 | 5,73 |
| PM8 | F | 65 | 4 | Aza | 961 | 8,74 |
| PM9 | F | 63 | 13 | Pred | 1279 | 16,9 |
| PM10 | F | 63 | 11 | MTX | 119 | 5,91 |
Patients with polymyositis (PM) were investigated for the frequencies of CD8+NKG2Dhigh T cells in peripheral blood and CK (creatinine kinase) levels in the serum.
Aza, azathioprine; CP, cyclophosphamide; IVIG, intravenous immunoglobulins; F, female; M, male; MTX, methotrexate; Pred, prednisolone.